2006年抗人类免疫缺陷病毒治疗研究新进展
摘要
高效联合抗逆转录病毒治疗（highly active antiretrovival therapy，HAART）是艾滋病的最主要治疗手段。2006年抗HIV治疗研究在诸多领域均取得了新的进展，国际艾滋病学会（International AIDS Society，IAS）和美国健康及人类服务部（Department of Health and Human Services，DHHS）。均依据新的研究成果对其艾滋病治疗指南进行了修订。以下就2006年国内外有关抗HIV治疗的最新进展综述如下。
出处
《中华内科杂志》
CAS
CSCD
北大核心
2007年第11期950-951,共2页
Chinese Journal of Internal Medicine
参考文献11
-
1Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel JAMA,2006 ,296 :827-843.
-
2DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: a working group of the office of AIDS research advisory council. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. [2006-10-10]. http:// aidsinfo. nih. gov/contentfLles/AdultandAdolescentGL_PDA. pdf
-
3Garcia F, de Lazzari E, Plana M, et al. Long-term CD4 + T-cell response to highly active antiretroviral therapy according to baseline CD4 + T-cell count. J Acquir Immune Defic Syndr,2004 ,36 :702- 713.
-
4A once-daily combination tablet ( Atripla ) for HIV. Med Lett Drugs Ther,2006,48:78-79.
-
5Poveda E, Blanco F, Garcia-Gasco P, et al. Successful rescue therapy with darunabir (TMCll4) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. AIDS, 2006,20 : 1558-1560.
-
6Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase Ⅱ randomised controlled trial. Lancet, 2007,369: 1261- 1269.
-
7Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of bevirimat ( PA-457 ), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother, 2007, 51 : 3063-3066.
-
8Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abaeavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet, 2006 ,368:476-482.
-
9DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis, 2004,39 : 1038 -1046.
-
10Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med,2006,354:251-260.
-
1邢卉春,王勤环,徐小元.人类免疫缺陷病毒感染的辅助受体及相关的抗人类免疫缺陷病毒治疗的研究进展[J].中华医学杂志,2002,82(22):1577-1581.
-
2美国推出抗HIV治疗新指南[J].传染病网络动态,2002(9):23-23.
-
3许侠,林乾.CD4较低的患者坚持抗HIV治疗至关重要[J].国外医学情报,2004,25(6):40-40.
-
4李思翘.发展中国家抗HIV治疗遇到的问题[J].国外医学情报,2003,24(12):33-33.
-
5郑晓琼（摘）.HIV治疗指南更加细化[J].国外药讯,2007(2):1-1.
-
6沈成利,吴昊.抗HIV治疗的副作用(一)——核苷类及非核苷类逆转录酶抑制剂[J].中国艾滋病性病,2005,11(3):228-229. 被引量：10
-
7李关汉,丁怡.抗艾滋病病毒治疗进展介绍[J].中国性病艾滋病防治,2000,6(5):308-310. 被引量：1
-
8李太生,孙越.抗HIV治疗对艾滋病病人免疫功能的影响[J].传染病信息,2001,14(1):8-9. 被引量：1
-
9周立杰.艾滋病治疗进展[J].世界最新医学信息文摘,2012,12(11):28-29.
-
10张美,张红,李旺泉,李群辉,吴昊,张宏伟.艾滋病长期免费抗病毒治疗疗效和换药原因分析[J].北京医学,2016,38(12):1286-1289. 被引量：5
